Bpc-157/Tb-500 5mg/5mg

Bpc-157/Tb-500 5mg/5mg

🧬 Overview — BPC-157 + TB-500 Mix

A BPC-157 + TB-500 blend refers to a research peptide stack combining two distinct synthetic peptides studied in preclinical settings for tissue repair, recovery support, angiogenesis, and inflammation modulation. They are often marketed together (sometimes called a “Wolverine Stack”) because each peptide has somewhat complementary actions in experimental models of healing and tissue regeneration.

🧪 BPC-157 — Breakdown

📌 Functional Summary

BPC-157 is a synthetic pentadecapeptide derived from a part of a naturally occurring protective protein found in human gastric juice. In preclinical studies, it has been associated with tissue healing, cytoprotective effects, anti-inflammatory modulation, and angiogenesis.

🔢 CAS Number

• 137525-51-0 — the commonly reported CAS number for BPC-157.

🧬 Amino Acid Sequence

• Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (often abbreviated GEPPPGKPADDAGLV).

⚖️ Molecular Formula

• C₆₂H₉₈N₁₆O₂₂ — representing all atoms in the peptide chain.

⚖️ Molecular Weight

• ≈1,419.5 Da (g/mol) — the approximate peptide mass.

🧬 Structure

• Linear peptide composed of 15 amino acids linked by peptide bonds, with various hydrophilic and hydrophobic side chains.

🧪 TB-500 — Breakdown

📌 Functional Summary

TB-500 is a synthetic peptide derived from an active region of thymosin β-4, a naturally occurring protein involved in cellular migration and tissue remodeling. It’s primarily studied in research settings for angiogenesis, wound healing, cell migration, and tissue regeneration.

🔢 CAS Number

• 885340-08-9 — the registered CAS number associated with the TB-500 peptide fragment.

🧬 Peptide/Fragment & Sequence

• Active fragment: Ac-LKKTETQ (heptapeptide representing residues 17–23 of thymosin beta-4).

🧬 Molecular Formula

• C₃₈H₆₈N₁₀O₁₄ — corresponding to the TB-500 fragment.

⚖️ Molecular Weight

• ≈889.0 g/mol (Da) — approximate molecular weight of the heptapeptide fragment.

🧬 Structure

• N-terminal acetylated heptapeptide containing the active binding/tracking region of the larger thymosin β-4 protein (sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln).

🧠 Research Context

BPC-157 and TB-500 each have overlapping but distinct experimental profiles:

• BPC-157 is studied for localized tissue support (e.g., tendons, gut lining) and anti-inflammatory effects.
• TB-500 is associated with broader systemic effects on cell migration, angiogenesis, and wound repair due to its actin-modulating region.

Together, in some preclinical stacks and anecdotal protocols, they are thought to enhance recovery, reduce inflammation, and promote regenerative processes more comprehensively than either alone — although these claims remain primarily unverified by rigorous human clinical trials and are research-phase at best.

⚠️ Safety & Regulatory Notes

• Both peptides are research chemicals and are not approved by the FDA for therapeutic use. They are often labeled “for research use only”.
• Both appear on anti-doping prohibited lists for athletic competition.
• Combining peptides into a single vial for injection is typically discouraged due to differing solution pH/stability requirements.

🧪 Combined/Stack Notes

• A BPC-157 + TB-500 peptide blend is essentially a co-administration of two distinct peptides, not a new molecule; each retains its individual molecular identity and functional profile.
• For documentation or protocol summaries, you can list each component separately with its sequence, weight, and CAS information as shown above.